Efficacy

In 2 clinical trials, CAPLYTA demonstrated statistically superior improvement vs placebo in symptoms of schizophrenia1

Study 1. CAPLYTA demonstrated significant improvement in PANSS (Positive and Negative Syndrome Scale) total score at Day 281,2*

This study was not designed to allow for efficacy comparison of CAPLYTA and risperidone.
Risperidone was included for assay sensitivity.1,2

78%

GREATER REDUCTION IN PANSS THAN PLACEBO
FOR CAPLYTA AT DAY 281

Study 2. Change from baseline in PANSS total score1,4*

Limitation: The weekly time points prior to Day 28 were not powered for statistical analysis and should be considered descriptive only. Therefore, the results require cautious interpretation and could represent chance findings.

41%

GREATER REDUCTION IN PANSS THAN PLACEBO
FOR CAPLYTA AT DAY 281

CAPLYTA demonstrated significant improvement
in Clinical Global Impression-Severity (CGI-S) scores3||

CGI-S was a secondary endpoint3

Patients on CAPLYTA 42 mg saw a 0.8 improvement in CGI-S score vs 0.5 on placebo (P <.05). Baseline CGI-S scores (mean) were 4.8 for CAPLYTA 42 mg and placebo.3

LSM=least squares mean.

The PANSS is a 30-item scale used to measure symptoms of schizophrenia. Each item is rated by a clinician on a 7-point scale. A score of 1 indicates the absence of symptoms, and a score of 7 indicates extremely severe symptoms. The PANSS total score may range from 30 to 210, with higher scores reflecting greater overall symptom severity.1

The CGI-S asks the clinician how mentally ill the patient is, which is rated on the following 7-point scale: 1=normal, not at all ill; 2=borderline ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients.5